ED&I logo
ED and I

Paving the Way for Diverse & Equitable Next Generation
Precision Medicine Clinical Trials

Establishing Collaborative Strategies to Improve Recruitment of Historically Marginalized Communities in Clinical Trials to Ensure Future Precision Medicines Are Fit For All

When: September 27, 7.30am – 5.00pm
Where: Boston - The Westin Boston Seaport District

Note: This meeting is taking place in-person only and online attendance will not be available

Under-represented racial and ethnic populations have a long history of being mistreated by the health care system, researchers and the government. While the goal of precision medicine is to help everybody, the current research is largely based on the genes of people who are predominantly of white and European descent. As an industry, it is our responsibility to leverage our position to influence and drive action towards greater clinical trial diversity, equity and inclusion for all communities around the world.

That is why, the 4th Equity, Diversity & Inclusion in Precision Medicine Summit is returning to Boston to tackle the key barriers and challenges to clinical trial participation and discuss how to better align precision medicine trial participants with consumer populations.

You can expect case studies, presentations, panel discussions, roundtable discussions and networking opportunities to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities.

Do not miss out on this opportunity and join 80+ thought leaders in Boston to pave the way for the future of precision medicine clinical trials!

2022 Expert Speaker Faculty:

Anas El Turabi

Partner

McKinsey

Cristina Candida Quarta

Senior Medical Director

Alexion AstraZeneca Rare Diseases

Dana Dornsife

Founder, Chief Mission & Strategy Officer

Lazarex Cancer Foundation

Daniel Simon

Senior Vice President, BioPharma Business Development

Guardant Health

Diana Merino Vega

Director, Oncology Translational Medicine Strategy & Portfolio

AstraZeneca

Elizabeth George

Senior Director, Diversity & Inclusion, Site & Patient Engagement

Labcorp Drug Development

Holly Smithson

Chief Executive Officer

Athena

Jasmine Sze

Director, Global Strategic Biomarkers Lead, Translational Medicine & Oncology Clinical Trial Diversity Lead

AstraZeneca

Leopold Sellner

Senior Medical Director

Takeda

Marcie Reeder

Director, Global Patient Affairs

BluePrint Medicines

Marjorie Petty, PhD, MSN

Senior Director, Clinical Operations & Medical Development

Spectrum Pharmaceuticals

Michaela Bowden

Senior Vice President, Biology & Translation

Flare Therapeutics

Qing Li, MD, PhD

Head of Clinical Biomarker & CDx Strategy

H3 Biomedicine

Samik Basu

Chief Scientific Officer

Cabaletta Bio

Siddha Kasar

Director, Oncology Precision Translational Medicine

Takeda

Tara Lehner

Vice President, Clinical Operations

Inmune Bio

Tiffany Patrick

Vice President, Patient Advocacy & Engagement

Alnylam Pharmaceuticals

Veronica Sandoval

Principal, Patient Inclusion & Health Equity, Chief Diversity Office

Genentech

Note: This meeting is taking place in-person only and online attendance will not be available. Registration to the summit is free, but the event is operating with limited capacity.

What Will We Cover?

Please note: This meeting is taking place in-person only and online attendance will not be available.

This is the key in-person meeting for any precision medicine expert looking to draw from the experience of leading pharma and biotechs to help establish clear guidelines, expertise and processes to improve diversity in precision medicine clinical trials and therefore, enhance drug safety, improve drug development, and support fair access to medicines for all patients.

BulletPoint iea 2

Address financial, geographical and trust burdens to clinical trial participation and how precision medicine is aiming to mitigate them

BulletPoint iea 2

Tap into real-world examples that enabled more inclusivity in trial, as well as tailored strategies to engage with different communities

BulletPoint iea 2

Discuss best practices and opportunities to address diversity and inclusion in DCTs and maximize clinical enrollment

BulletPoint iea 2

Identify strategies to improve genomic representation and have a better understanding of the disease

BulletPoint iea 2

Explore how to overcome unconscious bias in clinical healthcare to build a fairer future for patients

Note: This meeting is taking place in-person only and online attendance will not be available. Registration to the summit is free, but the event is operating with limited capacity.

What’s New in 2022?

From discussing practical steps to increase representation of historically marginalized communities in trials to highlighting how Decentralized Clinical Trials (DCTs) could help diversify the patient population, you can expect:

BulletPoint iea 2

Addressing Barriers to Increase Diversity in Precision Medicine Clinical Trials

BulletPoint iea 2

Translating Diversity in Leadership into Diversity in Clinical Enrollment

BulletPoint iea 2

Widening Your Global Patient Outreach with DCTs

BulletPoint iea 2

Building Inclusivity into Preclinical Precision Medicine Study Designs

BulletPoint iea 2

Discussing How to Overcome Unconscious Bias in Clinical Healthcare to Build a Fairer Future for Patients

VENUE

The World Clinical Biomarkers & CDx Summit and the Equity, Diversity & Inclusion in Precision Medicine Day will be held at:

The Westin Boston Seaport District
425 Summer St, Boston, MA, 02210

Proud to Partner With:

Roche_Logo.svg
guardantlogo
thumbnail_Labcorp_Oncology_ CROPPED

Note: This meeting is taking place in-person only and online attendance will not be available. Registration to the summit is free, but the event is operating with limited capacity.